Altre lingue Neurocrine Biosciences, Inc. Deutsche Boerse AG

Azioni

NB3

US64125C1099

Tempo reale stimato Tradegate Altri mercati azionari 15:22:59 11/07/2024			Variaz. 5gg	Var. 1 gen.
134,3 ^EUR	-0,98%		+5,88%	+13,55%

03/07	L'insider di Neurocrine Biosciences ha venduto azioni per un valore di 1.401.864 dollari, secondo un recente deposito SEC	MT
13/06	Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-13-2024 10:40 AM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU : Alphabet, Nike, Nvidia, Tesla, Starbucks...	03/07
ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks...	03/07
Neurocrine Biosciences Insider Sold Shares Worth $1,401,864, According to a Recent SEC Filing	03/07
Neurocrine Biosciences Says US FDA Accepts NDAs With Priority Review for Adrenal Gland Disease Drug	01/07
Neurocrine Biosciences Gets FDA Priority Review for Crinecerfont	01/07
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH	01/07
Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH	01/07
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell 1000 Defensive Index	01/07
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell 1000 Growth-Defensive Index	01/07
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer	06/06
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024	03/06
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	03/06
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	03/06
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	03/06
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	03/06
Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing	31/05
Neurocrine Biosciences to Participate at Investor Conferences in June	29/05
Neurocrine Biosciences to Present New Phase 3 CAHtalyst Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024	29/05
Neurocrine Biosciences Says CEO Kevin Gorman Retiring	28/05
Neurocrine founder-CEO Gorman to retire in October	28/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Neurocrine Biosciences, Inc. Deutsche Boerse AG

Azioni

NB3

US64125C1099

Altre lingue

Filtri